Company profile: Nabriva Therapeutics
1.1 - Company Overview
Company description
- Provider of innovative anti-infective agents to treat serious infections, including XENLETA (lefamulin) for adult CABP, IV and oral, FDA-approved; CONTEPO (fosfomycin) IV for complicated urinary tract infections, including acute pyelonephritis, active against multi-drug resistant strains; and BC-7013, a topical pleuromutilin candidate for Gram-positive infections, including uncomplicated skin and skin structure infections.
Products and services
- BC-7013: Topical pleuromutilin antibiotic candidate to treat Gram-positive infections, including uncomplicated skin and skin structure infections
- CONTEPO (fosfomycin for injection): Intravenous antibiotic targeting complicated urinary tract infections (cUTIs), including acute pyelonephritis, with activity against multi-drug resistant strains
- XENLETA (lefamulin): FDA-approved antibiotic for intravenous and oral administration used to treat adult community-acquired bacterial pneumonia (CABP), the first systemic pleuromutilin antibiotic
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nabriva Therapeutics
Resistell
HQ: Switzerland
Website
- Description: Provider of antibiotic resistance testing via Phenotech Multistar, an ultra-rapid Antibiotic Susceptibility Testing (AST) platform using nanomotion technology to deliver results in 2 hours independent of bacterial growth, and Phenotech Research, a research device measuring nanoscale cellular vibrations to study growth phenotypes and provide rapid test results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resistell company profile →
Gritstone Bio
HQ: United States
Website
- Description: Provider of immunotherapies for cancer and infectious diseases, including GRANITE, a personalized neoantigen vaccine for solid tumors; SLATE, an off-the-shelf shared-neoantigen immunotherapy for KRAS-driven tumors; CORAL, prophylactic vaccines using self-amplifying mRNA; an HIV vaccine collaboration with Gilead; and EDGE, an AI platform to identify T cell targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gritstone Bio company profile →
Artus Biotech
HQ: Germany
Website
- Description: Provider of DNA-based diagnostic kits focused on PCR and real-time PCR, developed, produced, and sold for detection of infectious agents and use in pharmacogenomics and veterinary applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artus Biotech company profile →
ITS Innovation
HQ: United Kingdom
Website
- Description: Provider of synthetic vaccines for mutating viruses using a T-cell vaccine platform that targets conserved viral antigens to direct immune responses, and of pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH, designed to reduce body weight, liver fat, serum lipids, and address liver fat and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ITS Innovation company profile →
Vaxcyte
HQ: United States
Website
- Description: Provider of vaccines and vaccine development technologies, including VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in adults (FDA Breakthrough Therapy); VAX-31, a 31-valent pneumococcal conjugate candidate; the XpressCF cell-free platform for site-specific conjugation to enhance immunogenicity; and preclinical programs for Group A Strep, periodontitis, and Shigella.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxcyte company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nabriva Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nabriva Therapeutics
2.2 - Growth funds investing in similar companies to Nabriva Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nabriva Therapeutics
4.2 - Public trading comparable groups for Nabriva Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →